Arrowstreet Capital, Limited Partnership Macrogenics Inc Transaction History

Arrowstreet Capital, Limited Partnership

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $701,088 - $1.58 Million	156,493 New	156,493 $1.51 Million
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $2.54 Million - $4.42 Million	-124,156 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$18.99 - $33.2 $2.76 Million - $4.82 Million	-145,172 Reduced 53.9%	124,156 $3.95 Million
Q4 2020 Feb 12, 2021	BUY	$19.41 - $26.0 $1.72 Million - $2.31 Million	88,670 Added 49.08%	269,328 $6.16 Million
Q3 2020 Nov 12, 2020	SELL	$24.69 - $31.6 $5.37 Million - $6.88 Million	-217,680 Reduced 54.65%	180,658 $4.55 Million
Q2 2020 Aug 12, 2020	BUY	$5.2 - $29.12 $1.81 Million - $10.1 Million	347,538 Added 684.13%	398,338 $11.1 Million
Q1 2020 May 15, 2020	BUY	$4.28 - $12.11 $217,424 - $615,188	50,800 New	50,800 $296,000
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $2.08 Million - $2.83 Million	-143,385 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $52,161 - $120,192	4,695 Added 3.39%	143,385 $2.58 Million
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $1.35 Million - $2.46 Million	115,027 Added 486.1%	138,690 $1.76 Million
Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $455,749 - $555,133	23,663 New	23,663 $507,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.